Want to join the conversation?
For FY17, $CLX expects a 2-4% sales growth, reflecting about 2 points of benefit from the RenewLife acquisition, partially offset by about 2% impact from unfavorable FX. Excluding the FX impact, $CLX expects sales growth of 4-6%. $CLX expects EBIT margin expansion to be 25-50BP, primarily driven by lower SG&A, which is expected to be below 14%.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.